Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
4.300
-0.130 (-2.93%)
Aug 12, 2026, 2:37 PM EDT - Market open
Insight Molecular Diagnostics Employees
As of December 31, 2025, Insight Molecular Diagnostics had 58 total employees, including 55 full-time and 3 part-time employees. The number of employees increased by 9 or 18.37% compared to the previous year.
Employees
58
Change (1Y)
9
Growth (1Y)
18.37%
Revenue / Employee
$28,793
Profits / Employee
-$851,017
Market Cap
138.85M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 58 | 9 | 18.37% | 55 | 3 |
| Dec 31, 2024 | 49 | 3 | 6.52% | 46 | 3 |
| Dec 31, 2023 | 46 | -30 | -39.47% | 43 | 3 |
| Dec 31, 2022 | 76 | -39 | -33.91% | 75 | 1 |
| Dec 31, 2021 | 115 | 64 | 125.49% | 110 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 1,002 |
| Burning Rock Biotech | 667 |
| MDxHealth | 364 |
| Freenome | 363 |
| Biodesix | 334 |
IMDX News
- 22 hours ago - Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing - GlobeNewsWire
- 1 day ago - Insight Molecular Diagnostics Earnings Call Transcript: Q2 2026 - Transcripts
- 1 day ago - Insight Molecular Diagnostics Shareholder letter: Q2 2026 - Filings
- 1 day ago - Insight Molecular Diagnostics Earnings release: Q2 2026 - Filings
- 1 day ago - Insight Molecular Diagnostics Quarterly report: Q2 2026 - Filings
- 1 day ago - Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c) - TheFly
- 8 days ago - iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - GlobeNewsWire
- 20 days ago - Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay - TheFly